Shu Wen1,2, Nan Chen3, Ying Hu1,4,5, Litao Huang6, Jin Peng1,2, Meina Yang1,2, Xiaoyang Shen1,2, Yang Song7, Liangzhi Xu1,4,5. 1. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. 2. West China School of Medicine, Sichuan University, Chengdu, China. 3. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University, Ministry of Education, Chengdu, China. 5. The Joint Laboratory for Reproductive Medicine of Sichuan University, The Chinese University of Hong Kong, Hong Kong, China. 6. Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China. 7. Department of Pharmacy Services Tacoma, St. Joseph Medical Center, CHI Franciscan Health System, Tacoma, WA, USA.
Abstract
BACKGROUND: Absolute monocyte count (AMC) is often used to be assessed in cancer follow-up, which has regained interest as a potential prognostic indicator in many solid tumors, though not consistently or comprehensively. In the present study, we set out to perform a comprehensive meta-analysis of all available data regarding the prognostic significance of AMC in solid tumors. We also evaluated the association between AMC and clinical features in solid tumors. METHODS: A hazard ratio (HR) and corresponding 95% confidence interval (CI) or a p value (p) from eligible studies were extracted and subsequently pooled analyzed. Subgroup analyses and meta-regression analyses were conducted according to the confounders of included studies. In addition, the relationships between AMC and clinical characteristics were also explored in the meta-analysis. RESULTS: Overall, ninety-three articles comprising 104 studies with 32229 patients were finally included. The results showed that elevated AMC was associated with worse overall survival (OS) (HR = 1.615; 95% CI: 1.475-1.768; p < 0.001), disease-free survival (DFS) (HR:1.488; 95% CI: 1.357-1.633; p < 0.001), progressive-free survival (PFS) (HR: 1.533; 95% CI: 1.342-1.751; p < 0.001) and cancer-specific survival (CSS) (HR: 1.585; 95% CI: 1.253-2.006; p < 0.001) in non-hematological tumors. Subgroup analyses according to each confounder further proved the consistent prognostic value of AMC in solid tumor outcomes. Moreover, elevated AMC was more likely to be observed in male group and patients with smoking history, and associated with longer tumor length and advanced T stage. CONCLUSION: In short, the meta-analysis found that elevated AMC might indicate poor long-term outcomes in non-hematologic cancers, thus AMC may be a valuable marker in the prognosis for patients with solid tumors.
BACKGROUND: Absolute monocyte count (AMC) is often used to be assessed in cancer follow-up, which has regained interest as a potential prognostic indicator in many solid tumors, though not consistently or comprehensively. In the present study, we set out to perform a comprehensive meta-analysis of all available data regarding the prognostic significance of AMC in solid tumors. We also evaluated the association between AMC and clinical features in solid tumors. METHODS: A hazard ratio (HR) and corresponding 95% confidence interval (CI) or a p value (p) from eligible studies were extracted and subsequently pooled analyzed. Subgroup analyses and meta-regression analyses were conducted according to the confounders of included studies. In addition, the relationships between AMC and clinical characteristics were also explored in the meta-analysis. RESULTS: Overall, ninety-three articles comprising 104 studies with 32229 patients were finally included. The results showed that elevated AMC was associated with worse overall survival (OS) (HR = 1.615; 95% CI: 1.475-1.768; p < 0.001), disease-free survival (DFS) (HR:1.488; 95% CI: 1.357-1.633; p < 0.001), progressive-free survival (PFS) (HR: 1.533; 95% CI: 1.342-1.751; p < 0.001) and cancer-specific survival (CSS) (HR: 1.585; 95% CI: 1.253-2.006; p < 0.001) in non-hematological tumors. Subgroup analyses according to each confounder further proved the consistent prognostic value of AMC in solid tumor outcomes. Moreover, elevated AMC was more likely to be observed in male group and patients with smoking history, and associated with longer tumor length and advanced T stage. CONCLUSION: In short, the meta-analysis found that elevated AMC might indicate poor long-term outcomes in non-hematologic cancers, thus AMC may be a valuable marker in the prognosis for patients with solid tumors.
Authors: Keehoon Jung; Takahiro Heishi; Omar F Khan; Piotr S Kowalski; Joao Incio; Nuh N Rahbari; Euiheon Chung; Jeffrey W Clark; Christopher G Willett; Andrew D Luster; Seok Hyun Yun; Robert Langer; Daniel G Anderson; Timothy P Padera; Rakesh K Jain; Dai Fukumura Journal: J Clin Invest Date: 2017-07-10 Impact factor: 14.808
Authors: Franz Kratochvill; Geoffrey Neale; Jessica M Haverkamp; Lee-Ann Van de Velde; Amber M Smith; Daisuke Kawauchi; Justina McEvoy; Martine F Roussel; Michael A Dyer; Joseph E Qualls; Peter J Murray Journal: Cell Rep Date: 2015-09-10 Impact factor: 9.423
Authors: Kwan Ho Lee; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Sung-Im Do; Seoung Wan Chae; Chan Heun Park Journal: BMC Cancer Date: 2018-10-01 Impact factor: 4.430